Caplin Point Laboratories announced its Q2 FY26 results, showing revenue of ₹564.41 Crores and PAT of ₹160.23 Crores. The board approved the appointment of Mr. Ashok Partheeban and Mr. Vivek Partheeban as Additional Directors and Vice-Chairmen, and Dr. K C John as an Additional Director (Non-Executive Independent), effective November 5, 2025. The company continues its growth trajectory with new appointments and strong financial performance.
Q2 FY26 Financial Performance
Caplin Point Laboratories reported a robust financial performance for Q2 FY26. Key highlights include:
- Total Revenue: ₹564.41 Crores, up 12.0% YoY
- Profit After Tax (PAT): ₹160.23 Crores, up 22.5% YoY
- Earnings Per Share: ₹20.32
The company’s H1 FY26 performance was also strong, with total revenue reaching ₹1,097.77 Crores and a PAT of ₹310.99 Crores. These figures demonstrate continued growth and profitability.
New Board Appointments
The Board of Directors approved the following key appointments, effective November 5, 2025:
- Mr. Ashok Partheeban: Additional Director and Vice-Chairman
- Mr. Vivek Partheeban: Additional Director and Vice-Chairman
- Dr. K C John: Additional Director (Non-Executive Independent)
Mr. Vivek Partheeban also relinquished his position as Chief Operating Officer. These appointments are subject to shareholder approval.
Auditor’s Review
Brahmayya & Co., Chartered Accountants, conducted an independent audit review, confirming that nothing has come to their attention that would cause them to believe the accompanying results contain any material misstatements.
Source: BSE
